This question will be resolved alongside the corresponding market on Polymarket: https://polymarket.com/event/hantavirus-vaccine-in-2026

Resolution criteria

This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No". The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.

Background

Hantaviruses are a family of viruses spread mainly by rodents and can cause varied disease syndromes in people worldwide. Hantavirus Pulmonary Syndrome (HPS) is a severe respiratory disease primarily found in the Americas, while Hemorrhagic Fever with Renal Syndrome (HFRS) is found more commonly in Europe and Asia.

Currently, there are no FDA-approved vaccines for any Hantavirus infection in humans. Treatment is primarily supportive, as there is no specific antiviral therapy available for Hantavirus infections. Research into vaccine candidates has been ongoing for years, but none have reached the stage of widespread commercial licensure in the United States.